Aboriginal and Torres Strait Islander health

January/February 2014

Klinefelter syndrome

A general practice perspective

Volume 43, No.1, January/February 2014 Pages 38-41

Elyssia Bourke

Amy Herlihy

Pamela Snow

Sylvia Metcalfe

David Amor


Klinefelter syndrome (KS) is a common genetic condition affecting one in 450 men, but is only diagnosed in fewer than half of those affected.


To increase awareness among general practitioners of their role in the diagnosis and management of KS.


KS has a highly varied phenotype comprising a range of physical and psychosocial features and comorbidities. For patients diagnosed with KS, a range of management strategies can be used to improve health outcomes and quality of life.

Klinefelter syndrome (KS) is a common genetic condition, affecting one in 450 men.1 KS is caused by the presence, in men, of one or more supernumerary X chromosomes. Most men with KS have a 47,XXY karyotype;2–3 however 20% have a variant form, which most commonly is the presence of higher numbers of X chromosomes (eg. 48,XXXY), or mosaicism for two or more cell populations (eg. 46,XY/47,XXY).2–3 Men with a mosaic picture typically present with a less severe phenotype than men with a 47,XXY karyotype.4–5 Conversely, the presence of higher numbers of X chromosomes (eg. 48,XXXY) results in a more severe phenotype and more pronounced learning difficulties.4–5

KS was first described in 1942 and defined by a clinical phenotype comprising tall stature with a feminine body type, gynaecomastia, small testes and infertility.6 More recent studies have demonstrated a broader phenotypic spectrum of KS with no single presentation.5–9 The physical characteristics, psychosocial difficulties and comorbidities shown by individuals with KS are highly varied, and this should be borne in mind when assessing an individual for the presence of KS.7–10 Most men with KS have a degree of androgen deficiency, to which a number of clinical features can be attributed.4 Men with KS are typically azoospermic and therefore are unable to conceive naturally.11

Currently, KS is significantly under-diagnosed: only 39% of men with KS receive a diagnosis postnatally.1 Even for those who are diagnosed, only 10% will receive their diagnosis before puberty.5 This can be attributed to the difficulty in diagnosing KS, due to the heterogeneous phenotypic presentation and the lack of awareness of KS.10,12

General practitioners can play a major part in improving health outcomes for men with KS through improved detection amongst their male patients. Ongoing care and management can then be provided in the general practice setting and through the use of appropriate referral pathways.

When to consider a diagnosis of KS

KS can be diagnosed at any age. Clinical features suggestive of KS are listed in Table 1, and clinical suspicion should be raised whenever two or more of these features are present. Currently, KS is diagnosed most commonly at one of four stages of life:

  1. during the prenatal period when diagnosis of KS at amniocentesis or chorionic villus sampling is usually an incidental finding
  2. in male children with a developmental delay and/or learning difficulties
  3. in young adult men with incomplete virilisation after puberty
  4. in men of reproductive age presenting with azoospermia (absent sperm).

Once the diagnosis of KS is suspected, it is easily confirmed by a simple chromosome test.

Table 1. Possible features of Klinefelter syndrome
Postnatal period
  • Micropenis
  • Cryptorchidism
  • Hypospadias
  • Simian palm crease
(Note: most individuals with KS will show no physical features during the postnatal period.)
  • Anxious
  • Easily upset
  • Introverted personality type (shy, passive)
  • Quiet baby
  • Easily fatigued
  • Low muscle tone and resulting comorbidities (eg. chronic constipation, sleep apnoea, abnormal posturing)
  • Increased relative height ± long arms and legs
  • Delayed developmental milestones
  • Lower verbal IQ and delays in reaching early language milestones
  • Language and learning problems including difficulties reading; expressive and receptive language problems, global speech delay
  • Difficulty socialising with others, fewer friends than other children
  • Body image issues
  • Depressed mood
  • Small firm testes
  • Poor virilisation including lack of facial, pubic and underarm hair
  • Gynaecomastia
  • Truncal obesity
  • Sexual dysfunction
  • Body image issues
  • Depressed mood
  • Infertility
  • Fatigue
  • Low libido
  • The continuation of a number of the features above is possible

Comorbidities associated with KS

KS is associated with an increased risk of a variety of comorbidities, resulting in life expectancy being reduced by 2–6 years, compared with 46,XY men.13 These comorbidities and their relative risks in men with KS are detailed in Table 2. Although some of these comorbidities can be attributed to androgen deficiency, for many, the reason for the increased relative risk is not known.

Table 2. Comorbidities associated with Klinefelter syndrome
ComorbidityRelative risk
  • Cancer (all types)
  • Breast
  • Mediastinal
  • Metabolic syndrome
  • Type II diabetes
  • Obesity
  • Endocrine diseases (all types)
  • Hypothyroidism
  • Venous thromboembolic disease
  • Pulmonary embolism
  • Osteoporosis
  • Fractures
  • Anaemia
  • Systemic lupus erythematosis (SLE)
  • Asthma
  • Epilepsy
  • Psychiatric disturbance
  • Depression
  • Psychosis

Management in general practice

Although no cure exists for KS, there are a number of treatment and management options that can have a positive impact on the quality of life for men with KS. For most management options, the earlier they are instigated, the greater the benefit.11

Testosterone replacement therapy (TRT) has been used with great success in men with KS. TRT can alleviate many of the features associated with KS, leading to improved mood, lessened fatigue, increased libido, heightened concentration, enhanced muscle strength and optimised bone mineral density.14 TRT has also been shown to prevent or alleviate many of the comorbidities associated with KS and to have a positive effect on general health and quality of life.3,14 However, it is important to note that TRT does not improve fertility in men with KS. When considering whether or not to use TRT, it is important to view serum testosterone and luteinizing hormone (LH) levels in combination, as it has been demonstrated that in the presence of raised LH levels, even men with normal serum testosterone levels will benefit from TRT.15 All men with KS should be referred to an endocrinologist for assessment and consideration of TRT, which is now available as implants, patches, gels, oral tablets and intramuscular injections.

It is important to make men with KS aware of the fertility options available to them. Until recently, men with KS were considered to be infertile, with sperm donation being the primary option for achieving fatherhood; however with the recent developments of in vitro fertilisation (IVF), some men with KS have been able to biologically father a child.16 In about 50% of men with KS who undergo testicular sperm extraction (TESE), sperm can be recovered from the testes;16 however, the success of the retrieval, and therefore live birth, is highly dependent on age. A progressive decline in successful retrieval rates has been demonstrated with increasing age; therefore men with KS should consider TESE as early as possible.17 For those men from whom sperm is recovered, pregnancy rates are around 20–25% per IVF cycle.18 Males with KS who have received an early diagnosis should be referred to a fertility specialist as an adolescent, or if a diagnosis is determined later than this stage of life, a referral should be offered at the time of diagnosis.19 Most offspring of men with KS have normal chromosomes; however, there is some evidence of an increased risk of chromosome abnormalities in general, and so prenatal diagnosis should be considered if pregnancy is achieved.

General practitioners have a role in monitoring men with KS for comorbidities, which are outlined in Table 2. A full blood examination, thyroid function test, cholesterol and fasting blood glucose levels should be performed every two years. In addition, DEXA scans can be considered because of the increased risk of osteoporosis.20 Men with KS may also benefit from allied health support. Although reliant on a case-by-case assessment, educational support, speech therapy, and physical and occupational therapy can be useful management strategies that can provide improved outcomes.21,22

Referral to a clinical geneticist should be considered, particularly for Men who have questions about the genetics of KS. Referral to a psychiatrist should also be considered where psychiatric comorbidities exist. Some KS men may also wish to be referred to a plastic surgeon for cosmetic bilateral mastectomy or liposuction.

Finally, all men with KS, and their parents if appropriate, should be offered the opportunity to be linked in with KS support groups. Support groups have been demonstrated to relieve some of the anxiety associated with a new diagnosis and the uncertainties surrounding prognosis.23 Individuals with KS can also be offered fact sheets available from the Andrology Australia website, which provides useful information about KS, including treatment and management options.

Key points

  • KS is a common genetic condition affecting one in 450 men, but it is only diagnosed in 40% of men.
  • KS has a broad phenotype, but some of the common features are increased height, small firm testes, azoospermia, symptoms of androgen deficiency, as well as difficulties with language, learning and psychosocial function.
  • Treatment and management strategies exist for KS and can provide good outcomes for these individuals, especially when initiated early.

Competing interests: None.
Provenance and peer review: Not commissioned; externally peer reviewed.


  1. Herlihy AS, Halliday JL, Cock ML, McLachlan RI. The prevalence and diagnosis rates of Klinefelter syndrome: an Australian comparison. Med J Aust 2011;194:24–28.
  2. Rey RA, Gottlieb S, Pasqualini T, et al. Are Klinefelter boys hypogonadal? Acta Paediatrica 2011;100:830–38.
  3. Boada R, Janusz J, Hutaff-Lee C, Tartaglia N. The cognitive phenotype in Klinefelter syndrome: A review of the literature including genetic and hormonal factors. Dev Disabil Res Rev 2009;15:284–94.
  4. Zinn AR, Ramos P, Elder FF, Kowal K, Samango-Sprouse C, Ross JL. Androgen Receptor CAGn Repeat Length Influences Phenotype of 47,XXY (Klinefelter) Syndrome. J Clin Endocrinol Metab 2005;90:5041–46.
  5. Bojesen A, Juul S, Gravholt CH. Prenatal and Postnatal Prevalence of Klinefelter Syndrome: A National Registry Study. J Clin Endocrinol Metab 2003;88:622–26.
  6. Klinefelter HF. Klinefelter’s syndrome: historical background and development. South Med J 1986;79:1089–93.
  7. Herlihy AS, McLachlan RI, Gillam L, Cock ML, Collins V, Halliday JL. The psychosocial impact of Klinefelter syndrome and factors influencing quality of life. Genet Med 2011;13:632–42.
  8. Bojesen A, Juul S, Birkebæk N, Gravholt CH. Increased Mortality in Klinefelter Syndrome. J Clin Endocrinol Metab 2004;89:3830–34.
  9. Bojesen A, Juul S, Birkebæk NH, Gravholt CH. Morbidity in Klinefelter Syndrome: A Danish Register Study Based on Hospital Discharge Diagnoses. J Clin Endocrinol Metab 2006;91:1254–60.
  10. Bourke E, Snow P, Herlihy A, Amor D, Metcalfe S. A qualitative exploration of mothers’ and fathers’ experiences of having a child with Klinefelter syndrome and the process of reaching this diagnosis. Eur J Hum Genet 2013 22 May [Epub ahead of print].
  11. Forti G, Corona G, Vignozzi L, Krausz C, Maggi M. Klinefelter’s syndrome: a clinical and therapeutical update. Sex Dev 2010;4:249–58.
  12. Herlihy A, Halliday J, McLachlan R, Cock M, Gillam L. Assessing the risks and benefits of diagnosing genetic conditions with variable phenotypes through population screening: Klinefelter syndrome as an example. J Community Genet 2010;1:41–46.
  13. Bojesen A, Stochholm K, Juul S, Gravholt CH. Socioeconomic Trajectories Affect Mortality in Klinefelter Syndrome. J Clin Endocrinol Metab 2011;96:2098–104.
  14. Bojesen A, Høst C, Gravholt CH. Klinefelter’s syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 2010;16:396–401.
  15. Aksglaede L, Jensen RB, Carlsen E, et al. Increased basal and pulsatile secretion of FSH and LH in young men with 47,XXY or 46,XX karyotypes. Eur J Endocrinol 2008;158:803–10.
  16. Damani MN, Mittal R, Oates RD. Testicular tissue extraction in a young male with 47,XXY Klinefelter’s syndrome: potential strategy for preservation of fertility. Fertil Steril 2001;76:1054–56.
  17. Okada H, Goda K, Yamamoto Y, et al. Age as a limiting factor for successful sperm retrieval in patients with nonmosaic Klinefelter’s syndrome. Fertil Steril 2005;84:1662–64.
  18. Maiburg M, Hoppenbrouwers A, van Stel H, Giltay J. Attitudes of Klinefelter men and their relatives towards TESE-ICSI. J Assist Reprod Genet 2011;28:809–14.
  19. Groth KA, Skakkebaek A, Host C. Klinefelter syndrome – a clinical update. J Clin Endocrinol Metab 2013; 98:20–30.
  20. Akesglade L, Link K, Giwercman A, et al. 47,XXY Klinefelter syndrome: clinical characteristics and age-specific recommendations for medical management. Am J Med Genet 2013;163C:55–63.
  21. Bailey DB, Skinner D, Warren SF. Newborn Screening for Developmental Disabilities: Reframing Presumptive Benefit. Am J Public Health 2005;95:1889–93.
  22. Graham JM, Bashir AS, Stark RE, Silbert A, Walzer S. Oral and Written Language Abilities of XXY Boys: Implications for Anticipatory Guidance. Pediatr 1988;81:795–806.
  23. Halm MA. Effects of support groups on anxiety of family members during critical illness. Heart Lung 1990;19:62–71.
  24. Handelsman DJ, Liu PY. Klinefelter’s Syndrome – A Microcosm of Male Reproductive Health. Heart Lung 2006;91:1220–22.
  25. Brinton LA. Breast cancer risk among patients with Klinefelter syndrome. Acta Paediatrica 2011;100:814–18.
  26. Wistuba J. Animal models for Klinefelter’s syndrome and their relevance for the clinic. Mol Hum Reprod 2010;16:375–85.
  27. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003;26:76–83.
  28. Di Mambro A, Ferlin A, De Toni L, Selice R, Caretta N, Foresta C. Endothelial progenitor cells as a new cardiovascular risk factor in Klinefelter’s syndrome. Int J Androl 2010;16:411–17.
  29. Ferlin A, Schipilliti M, Vinanzi C, et al. Bone Mass in Subjects with Klinefelter Syndrome: Role of Testosterone Levels and Androgen Receptor Gene CAG Polymorphism. J Clin Endocrinol Metab 2011;96:E739–45.
  30. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: Support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum 2008;58:2511–17.
  31. Boks M, de Vette M, Sommer IE, et al. Psychiatric morbidity and X-chromosomal origin in a Klinefelter sample. Schizophr Res 2007;93:399–402.
  32. Turriff A, Levy HP, Biesecker B. Prevalence and psychosocial correlates of depressive symptoms among adolescents and adults with Klinefelter syndrome. Genet Med 2011;13:966–72.

Correspondence afp@racgp.org.au

Yes     No

Declaration of competing interests *

Yes No

Additional Author (remove)

Yes No






Competing Interests: 

Your comment is being submitted, please wait


Download citation in RIS format (EndNote, Zotero, RefMan, RefWorks)

Download citation in BIBTEX format (RefMan)

Download citation in REFER format (EndNote, Zotero, RefMan, RefWorks)

For more information see Wikipedia: Comparison of reference management software